Tag: Medtronic

IN.PACT Admiral DCB receives FDA approval for long SFA lesions

Medtronic has announced that it has received US Food and Drug Administration (FDA) approval for the IN.PACT Admiral drug-coated balloon (DCB) to treat long superficial...

IN.PACT SFA Japan trial shows significantly higher patency compared with PTA...

New two-year results from the IN.PACT SFA Japan trial were presented at the Leipzig Interventional Course (LINC; 30 January–2 February, Leipzig, Germany) by Osamu...

How would you treat these lesions?

This educational supplement is for distribution within Europe only. In this supplement: The rationale of directional atherectomy and DCB angioplasty for the treatment of “no-stent zones” CASE #1:...

First data from head-to-head comparison of Ranger and IN.PACT drug-coated balloons...

Early data from the first randomised controlled trial to compare two drug-coated balloons (DCBs) suggest that the primary patency obtained with the Ranger DCB...

ENCHANT will evaluate ChEVAR technique with Endurant II/IIs stent graft system

The post-market, non-interventional, multicentre, non-randomised, single-arm study will enroll approximately 150 patients across 25 sites in Europe and Russia, and will evaluate the safety...

Medtronic launches ChEVAR parallel graft technique study using Endurant II/IIs

Medtronic has announced the launch of the ENCHANT (Endurant ChEVAR New Indication Trial) study. The post-market, non-interventional, multi-centre, non-randomised, single-arm study will enrol approximately...

Endurant II/IIs stent graft receives FDA approval for short neck anatomies...

  Medtronic has received US Food and Drug Administration (FDA) approval for the Endurant II/IIs stent graft system to treat abdominal aortic aneurysm (AAA) patients...

From SYMPLICITY HTN-1 to SPYRAL HTN-OFF MED: The story of renal...

It is now almost a decade since the first patient underwent catheter-based renal denervation as a participant in a safety and proof-of concept study...

Medtronic launches Concerto 3D detachable coil system in USA and Europe

Medtronic is expanding its embolisation product portfolio with the launch of the Concerto 3D detachable coil system. The system was launched at the Cardiovascular...

Five-year ENGAGE data demonstrate comparable EVAR outcomes in male and female...

Five-year data from Medtronic’s ENGAGE global registry indicate that endovascular aneurysm repair (EVAR) outcomes are comparable between male and female patients when using the...

Two- and four-year IN.PACT Admiral drug-coated balloon data indicate good mid-...

Medtronic has released data reinforcing the durability and safety of the IN.PACT Admiral drug-coated balloon (DCB) in patients with peripheral artery disease (PAD). The...

First patient enrolled in study of Medtronic IN.PACT arteriovenous access drug-coated...

The first patient has been enrolled in Medtronic’s IN.PACT arteriovenous (AV) access drug-coated balloon (DCB) study for use in patients with end-stage renal disease. The...

QT Vascular enters into asset purchase option agreement with Medtronic

QT Vascular has entered into an asset purchase option agreement with Medtronic for the acquisition of the group's non-drug coated Chocolate percutaneous transluminal angioplasty...

Five-year Medtronic ENGAGE Registry data show positive real-world outcomes for Endurant...

Medtronic has reported that its Endurant II abdominal aortic aneurysm (AAA) stent graft system continues to demonstrate long-term durability and consistent outcomes in a...

Consistent results for Medtronic IN.PACT Admiral in complex peripheral artery disease...

Two new sub-analyses from the IN.PACT Global Study of the IN.PACT Admiral in patients with peripheral artery disease have been reported at the annual...

Leaving nothing behind: Is it time to move away from primary...

This educational supplement is only available in countries in Europe. This educational supplement explores the concept of “leaving nothing behind" in the treatment of the superficial...

Medtronic launches European below-the-knee clinical study of drug-coated balloon

Medtronic has launched the IN.PACT BTK study to evaluate the effectiveness of using a drug-coated balloon in patients with below-the-knee (BTK) peripheral artery disease. This...

Global cohorts report drug-coated balloon success above the knee and “promising”...

Three global registries reported fresh data at the 2017 Leipzig Interventional Course (LINC; 24–27 January, Leipzig, Germany), all of which showed encouraging outcomes for...

Promising 12- and 24-month East Asian experiences for drug-coated balloons

Results from two Asian studies presented at LINC 2017 (24–27 January, Leipzig, Germany), show encouraging outcomes for drug-coated balloon versus percutaneous transluminal angioplasty treatment...

Medtronic announces Health Canada licence for IN.PACT Admiral drug-coated balloon

Medtronic Canada, a subsidiary of Medtronic, has announced it has obtained Health Canada licence for the IN.PACT Admiral drug-coated balloon. IN.PACT Admiral is a primary...

Japanese IN.PACT SFA study demonstrates clinical outcomes consistent with other trials

The one-year clinical outcomes from the MDT-2113 IN.PACT SFA Japan trial have been released. The data was recently presented by Osamu Iida, Kansai Rosai...

Medtronic to distribute QT Vascular’s Chocolate balloon worldwide

QT Vascular has signed a definitive agreement with Medtronic, for the worldwide distribution of its Chocolate percutaneous transluminal angioplasty (PTA) catheter for a period...

US FDA grants Medtronic investigational device exemption for IN.PACT Admiral AV...

Medtronic has received an investigational device exemption (IDE) from the US Food and Drug Administration (FDA) to initiate a study of the IN.PACT Admiral...

Results from Asia and Belgium demonstrate consistent results from Medtronic IN.PACT...

New data presented at the 2017 Leipzig Interventional Course (LINC) have demonstrated strong efficacy and consistent outcomes for Medtronic’s IN.PACT Admiral drug-coated balloon across...

VeClose trial indicates 24-month non-inferiority of VenaSeal versus radiofrequency ablation

Two-year outcomes of the VeClose pivotal trial have been reported, showing a 94.3% closure rate and “continued non-inferiority results to radiofrequency ablation” when using...

Medtronic receives CE mark for lower-profile HawkOne directional atherectomy system

Medtronic has been granted CE mark approval for the HawkOne directional atherectomy system in a lower profile size for treating patients with peripheral artery...

Scott Hutton appointed general manager of Vascular Intervention at Spectranetics

Scott Hutton has been named general manager of Vascular Intervention at Spectranetics. In this role, Hutton will report directly to the president and chief executive...

Medtronic Endurant II/IIs granted CE mark for ChEVAR parallel graft technique

Medtronic has received CE mark for its Endurant II/IIs stent graft system to treat abdominal aortic aneurysm patients using a ChEVAR procedure—a parallel graft...

VEITH 2016: New data support strength and durability of Endurant II/IIs...

Medtronic announced data supporting the strength and durability of the Endurant II/IIs stent graft system to treat abdominal aortic aneurysm patients. The results, presented...

Valiant Captivia stent graft shows 90% freedom from dissection-related mortality at...

The Valiant Captivia thoracic stent graft system (Medtronic) has demonstrated freedom from all-cause mortality of 79.4% and freedom from dissection-related mortality of 90% at...

Medtronic receives FDA clearance of TrailBlazer angled peripheral support catheter

The US Food and Drug Administration (FDA) has cleared Medtronic’s TrailBlazer angled support catheter for use in the peripheral vascular system. The TrailBlazer angled support...

Medtronic Valiant Captivia demonstrates safety and efficacy at three years

Medtronic has announced new data, demonstrating safety and efficacy at three years in acute complicated type B aortic dissection patients treated with the Valiant Captivia thoracic...

New data demonstate durability, safety and efficacy for Medtronic’s In.Pact Admiral...

New data, presented in a series of late-breaking clinical trial presentations at the Vascular Interventional Advances (VIVA) 2016 conference in Las Vegas, USA, have...

US FDA approves first drug-coated balloon for treatment of in-stent restenosis

The US Food and Drug Administration (FDA) has approved Medtronic’s IN.PACT Admiral drug-coated balloon as a treatment for in-stent restenosis in patients with peripheral...

WAVES trial shows 100% vein closure at one month with short...

A post-market evaluation of the VenaSeal closure system (Medtronic) has found that, at one month, 100% of treated veins remained closed, quality of life...

REALITY trial enrols first patient in study evaluating Medtronic directional atherectomy...

Medtronic and VIVA Physicians reported on 27 July 2016 the first patient enrolled in the REALITY Study. The VIVA-sponsored study is assessing outcomes for...

Medtronic receives FDA approval for IN.PACT Admiral DCB 150mm lengths

Medtronic has received US Food and Drug Administration (FDA) approval for the IN.PACT Admiral drug-coated balloon (DCB) in longer, 150mm lengths. The 150mm length...